The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model

Pharmacopsychiatry

Volumn 46, Issue 1, 2013, Pages 1-9

  Von Wilmsdorff, M ^a   Bouvier, M L ^a   Henning, U ^a   Schmitt, A ^b,c,d   Schneider Axmann, T ^b,d   Gaebel, W ^a  

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

clozapine; haloperidol; metabolic syndrome; sex dependence

Indexed keywords

ADIPONECTIN; CHOLESTEROL; CLOZAPINE; GHRELIN; HALONEUROL; HALOPERIDOL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT ASPIRATION BIOPSY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FLUID INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEX DIFFERENCE; SPRAGUE DAWLEY RAT; WEIGHT GAIN;

ADIPOSITY; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CLOZAPINE; DRINKING; EATING; FEMALE; HALOPERIDOL; HORMONES; INSULIN; LIPIDS; MALE; METABOLIC SYNDROME X; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; WEIGHT GAIN;

EID: 84872686641     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1321907     Document Type: Article

References (71)

1. Henderson D. C. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry: 2005; 66 06 11 20 (Pubitemid 41243257)
2. Sacks F. M. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry: 2004; 65 18 3 12
3. Jones L. E., Carney C. P. Increased risk for metabolic syndrome in persons seeking care for mental disorders. Ann Clin Psychiatry: 2006; 18 149 155 (Pubitemid 44576435)
4. McEvoy J. P., Meyer J. M., Goff D. C. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res: 2005; 80 19 32 (Pubitemid 41587460)
5. Casey D. E., Haupt D. W., Newcomer J. W. et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry: 2004; 65 07 4 18
6. Guo J. J., Keck P. E. Jr, Corey-Lisle P. K. et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar order: A retrospective, population-based, case-control study. J Clin Psychiatry: 2006; 67 1055 1061 (Pubitemid 44230876)
7. Thakore J. H., Mann J. N., Vlahos I. et al. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obesity: 2002; 26 137 141 (Pubitemid 34098681)
8. Ryan M. C., Collins P., Thakore J. H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry: 2003; 160 284 289 (Pubitemid 41110453)
9. Arranz B., Rosel P., Ramirez N. et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naïve first-episode schizophrenia patients. J Clin Psychiatry: 2004; 65 1335 1342
10. Sengupta S., Parrilla-Escobar M. A., Klink R. et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res: 2008; 102 329 336
11. Wu M. K., Huang C. Y., Liou Y. J. et al. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obesity: 2008; 32 436 442 (Pubitemid 351414817)
12. Baptista T., La Cruz A., Mendoza S. et al. Endocrine and metabolic abnormalities involved in the obesity associated to typical antipsychotic drug administration. Pharmacopsychiatry: 2001; 34 223 231 (Pubitemid 33086855)
13. Bergman R. N., Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry: 2005; 66 504 514 (Pubitemid 40593580)
14. De Hert M. A., van Winkel R., van Eyck D. et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res: 2006; 83 87 93
15. Lamberti J. S., Olson D., Crilly J. F. et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry: 2006; 163 1273 1276 (Pubitemid 44464457)
16. Brixner D. I., Said Q., Corey-Lisle P. K. et al. Naturalistic impact of second-generation antipsychotics on weight gain. Am Pharmacother: 2006; 40 626 632
17. Melkersson K. I., Dahl M. L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics of clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology: 2003; 170 157 166 (Pubitemid 37421527)
18. Henderson D. C., Cagiero E., Copeland P. M. et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry: 2005; 62 19 28 (Pubitemid 40096067)
19. Ascher-Svanum H., Stensland M., Zhao Z. et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry: 2005; 5 3 16
20. Wu R. R., Zhao J. P., Zhai J. G. et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol: 2007; 27 374 379
21. Shehata M., Kamel M. A. Protective effect of antioxidant adjuvant treatment with hormone replacement therapy against cardiovascular diseases in ovariectomized rats. Endocr Regul: 2008; 42 69 75
22. Demissie M., Lazic M., Foecking E. M. et al. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab: 2008; 295 E262 E268
23. Pouzet B., Mow T., Kreilgaard M. et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav: 2003; 75 133 140 (Pubitemid 36577588)
24. Cooper G. D., Harrold J. A., Halford JC G. et al. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 428 436 (Pubitemid 351178959)
25. Choi S., Disilvio B., Unangst J. et al. Effect of chronic infusion of alanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci: 2007; 81 1024 1030 (Pubitemid 47384786)
26. Wiley J. L. Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats. Eur J Pharmacol: 2008; 578 216 221 (Pubitemid 350309576)
27. Baptista T., Parada M., Hernandez L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav: 1987; 27 399 405 (Pubitemid 17107006)
28. Baptista T., de Baptista E. A., Ying Kin NM K. et al. Comparative effects of the antipsychotics sulpiride or risperidone in rats I. bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res: 2002; 957 144 151 (Pubitemid 35346582)
29. Wilmsdorff M., Bouvier M. L., Henning U. et al. The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics: 2010; 65 1 10
30. Mercer J. G., Archer Z. A. Diet-induced obesity in the Sprague-Dawley rat: dietary manipulations and their effect on hypothalamic neuropeptide energy balance systems. Biochem Soc Trans: 2005; 33 1068 1072 (Pubitemid 41659115)
31. Assié M. B., Carilla-Durand E., Bardin L. et al. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol: 2008; 592 160 166
32. Tulipano G., Rizzetti C., Bianchi I. et al. Clozapine-induced alteration of glucose homeostasis in the rat: contribution of hypothalamic-pituitary- adrenal axis activation. Neuroendocrinology: 2007; 85 61 70 (Pubitemid 46725692)
33. Minet-Ringuet J., Even P. C., Goubern M. et al. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermic alteration. Appetite: 2006; 46 254 262 (Pubitemid 43867820)
34. Minet-Ringuet J., Even P. C., Lacroix M. et al. A model for antipsychotic-induced obesity in the male rat. Psychopharmacology: 2006; 187 447 454 (Pubitemid 44200516)
35. Boyda H. N., Tse L., Procyshyn R. M. et al. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci: 2010; 31 484 497
36. Wiley J. L., Evans R. L. Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats. Pharmacol Res: 2008; 58 240 246
37. Lemieux H., Blier P., Dutil J. D. Do digestive enzymes set a physiological limit on growth rate and food conversion efficiency in the Atlantic cod (Gadus morhua)? Fish Physiol Biochem: 1999; 20 293 303 (Pubitemid 129644137)
38. Kapur S., Wadenberg M. L., Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry: 2000; 45 241 246 (Pubitemid 30345844)
39. Perez-Costas E., Guidetti P., Melendez-Ferro M. et al. Neuroleptics and animal models: Feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm: 2008; 115 745 753
40. Remington G., Mann S., McCormick P. et al. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacol Biochem Behav: 2011; 100 86 89
41. Lightfoot J. T. Sex hormones regulation of rodent physical activity: a review. Int J Biol Sci: 2008; 4 126 132 (Pubitemid 351872043)
42. Kühn E. R., Bellon K., Huybrechts L. et al. Endocrine differences between the Wistar and Sprague Dawley laboratory rat: influence of cold adaption. Horm Metabol Res: 1983; 15 491 498 (Pubitemid 13010875)
43. Cacho J., Sevillano J., de Castro J. et al. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague Dawley rats. Am J Physiol Endocrinol Metab: 2008; 295 E1269 E1276
44. Chovan J. P., Yu E., Ring S. C. Metabolic differences between Sprague Dawley and Wistar Han male rats. ISSX Poster and oral presentations: 2007
45. Gao X., Zhao A., Zhou M. et al. GC/MS-based urinary metabolomics reveals systematic differences in metabolism and ethanol response between Sprague-Dawley and Wistar rats. Metabolomics: 2011; 7 363 374
46. Jassim G., Skrede S., Vázques M. J. et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology: 2012; 219 783 794
47. Sertié A. L., Suzuki A. M., Sertié RA L. et al. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Prog Neuro-Psychopharmacol Biol Psychiatry: 2011; 35 1884 1890
48. Newcomer J. W., Haupt D. W., Fucetola R. et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry: 2002; 59 337 345 (Pubitemid 34275252)
49. Jang I., Hwang D., Lee J. et al. Physiological difference between dietary obesity-susceptible and obesity-resistant Sprague Dawley rats in response to moderate high fat diet. Exp Anim: 2003; 52 99 107 (Pubitemid 41349973)
50. Leibowitz K. L., Chang G. Q., Pamy P. S. et al. Weight gain model in prepupertal rats: prediction and phenotyping of obesity-prone animals at normal body weight. Int J Obesity: 2007; 31 1210 1221 (Pubitemid 47172624)
51. Yang S. J., Denbow D. M. Interaction of leptin and nitric oxide on food intake in broilers and Leghorns. Physiol Behav: 2007; 92 651 657 (Pubitemid 350016127)
52. Calapai G., Caputi A. P. Nitric oxide and drinking behavior. Regul Pept: 1996; 66 117 121
53. Murashita M., Kusumi I., Hosoda H. et al. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology: 2007; 32 777 784 (Pubitemid 47187574)
54. Esen-Danaci A., Sarandöl A., Taneli F. et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 1434 1438
55. Giovambattista A., Piermaria J., Suescun M. O. et al. Direct effect of ghrelin on leptin production by cultured rat white adipocytes. Obesity: 2006; 14 19 38
56. Hanssens L., van Winkel R., Wampers M. et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res: 2008; 106 308 314
57. Hägg S., Söderberg S., Ahrén B. et al. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry: 2001; 62 843 848 (Pubitemid 33131169)
58. Emsley R., Turner J. H., Schronen J. et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol: 2005; 8 175 182 (Pubitemid 40769258)
59. Flanagan R. J., Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp: 2008; 23 27 41 (Pubitemid 351166610)
60. Chae B. J., Kang B. J. The effect of clozapine on blood glucose metabolism. Hum Psychopharmacol: 2001; 16 265 271
61. Smith G. C., Chaussade C., Vickers M. et al. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologica: 2008; 51 2309 2317
62. Best L., Yates A. P., Reynolds G. P. Actions of antipsychotic drugs on pancreatic β-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacol: 2005; 19 597 601 (Pubitemid 41578820)
63. Lindenmayer J. P., Czobor P., Volavka J. et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry: 2003; 160 290 296 (Pubitemid 41110454)
64. Kimura F., Natsusaka J., Endo Y. et al. Effect of dose of fat and fat content of the maintenance diet on postprandial serum triglyceride in rats. J Oleo Science: 2004; 53 515 520
65. Stairs D. J., Prendergast M. A., Bardo M. T. Environmental-induced differences in corticosterone and glucocorticoid receptor blockade of amphetamine self-administration in rats. Psychopharmacology: 2011; 218 293 301
66. Zhuravliova E., Barbakadze T., Zaalishvili E. et al. Social isolation in rats inhibits oxidative metabolism, decreases the content of mitochondrial K-Ras and activates mitochondrial hexokinase. Behav Brain Res: 2009; 205 377 383
67. Munetsuna E., Hattori M., Komatsu S. et al. Social isolation stimulates hippocampal estradiol synthesis. Biochem Biophys Res Commun: 2009; 379 480 484
68. Héliès J. M., Diane A., Langlois A. et al. Comparison of fat storage between Fischer 344 and obesity-resistant Lou/C rats fed different diets. Obesity Res: 2005; 13 3 10
69. Wu B., Du Y., Liu C. et al. Effect of repeated fasting/reffeding on body weight weight control and energy balance regulation in rats. Wei Sheng Yan Jiu: 2010; 39 601 605
70. Ghibaudi L., Cook J., Farley C. et al. Fat intake affects adiposity, comorbidity factors, and energy metabolism of Sprague Dawley rats. Obesity Res: 2002; 10 956 963 (Pubitemid 135688910)
71. Eckel L. A., Houpt T. A., Geary N. Spontaneous meal patterns in female rats with and without access to running wheels. Physiol Behav: 2000; 70 397 405